adapalene vs pimecrolimus
PlainMeds reviewed this comparison against our methodology in August 2026. It places FDA and CMS record fields side by side, without recommending either medication.
Side-by-side comparison of adapalene and pimecrolimus. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
Differin
Elidel
No summary available.
Pimecrolimus cream (Elidel) is a medicine that can help with eczema. It is used when other treatments have not worked well enough or are not a good choice for you.
Information not available.
This cream treats mild to moderate eczema, also known as atopic dermatitis. You can use it if other creams or medicines have not worked for you. It is for adults and children who are at least 2 years old and whose immune system works normally.
Information not available.
Pimecrolimus cream is a calcineurin inhibitor. It works by reducing inflammation in the skin. This helps to relieve itching and rash caused by eczema.
- • Dry skin
- • Contact dermatitis (skin rash)
- • Burning feeling on the skin where you put the medicine
- • Skin irritation
- • Burning feeling on the skin where you put the cream
- • Headache
- • Runny nose
- • Cough
- • Flu
- Dry Skin 44,990
- Skin Burning Sensation 41,633
- Acne 39,264
- Erythema 38,379
- Skin Irritation 26,225
- Dermatitis Atopic 178
- Rash 169
- Pruritus 160
- Eczema 80
- Dry Skin 79
No specific warnings noted.
Using this medicine for a long time may have risks. In rare cases, some people using similar medicines have gotten cancer, like skin cancer or lymphoma. Do not use this cream on children under 2 years old.
No pregnancy information available.
If you are pregnant, only use this cream if the benefit is greater than the risk to your baby. Talk to your doctor before using this medicine if you are breastfeeding.
Also Compare, Nearby Drugs
Compare adapalene with
Compare pimecrolimus with
How to Read This adapalene vs pimecrolimus Comparison
adapalene is classified in the Retinoid (Topical) drug class, while pimecrolimus sits within the Calcineurin Inhibitor (Topical) class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are split between OTC and prescription status, which affects access and supervision.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, adapalene has 190,491 submissions while pimecrolimus has 666. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. No direct interaction between these two drugs is listed in our FDA-derived dataset, though co-prescription still warrants pharmacist review. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for adapalene or pimecrolimus.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.